← Back to Search

CADENCE Program for Opioid Use Disorder in Pregnancy (CADENCE Trial)

N/A
Waitlist Available
Led By Jennifer Marshall, MD
Research Sponsored by University of South Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with known opioid use disorder over the age of 18 years old who are pregnant
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up prenatal up to 1 year old
Awards & highlights

CADENCE Trial Summary

This trial seeks to improve outcomes for mothers and babies affected by opioid use disorders. It will examine data and programs to better understand and support these families.

Who is the study for?
This trial is for pregnant individuals over the age of 18 who have been diagnosed with opioid use disorder. It's not open to those under 18, incarcerated individuals, non-pregnant people, or patients without an opioid use disorder.Check my eligibility
What is being tested?
The CADENCE program is being tested in this study. It aims to improve outcomes for mothers and infants affected by opioid use disorders by using public health and clinical data to inform care.See study design
What are the potential side effects?
Since the intervention involves a program rather than a medication, traditional side effects are not applicable. However, participants may experience stress or discomfort related to participation in the program.

CADENCE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am over 18, pregnant, and have an opioid use disorder.

CADENCE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~prenatal up to 1 year old
This trial's timeline: 3 weeks for screening, Varies for treatment, and prenatal up to 1 year old for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Decreased pharmacologically treated NOWS
MOUD at delivery hospitalization
Secondary outcome measures
Breastfeeding at discharge
Department of Children and Families out-of-home placement
Enrollment in community supports and services.
+5 more
Other outcome measures
Acceptability of CADENCE Program
Feasibility of CADENCE Program
Trialability of CADENCE Program

CADENCE Trial Design

1Treatment groups
Experimental Treatment
Group I: CADENCE program pilotExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

University of South FloridaLead Sponsor
402 Previous Clinical Trials
185,154 Total Patients Enrolled
Jennifer Marshall, MDPrincipal InvestigatorUniversity of South Florida
Kimberly Fryer, MDPrincipal InvestigatorUniversity of South Florida

Media Library

CADENCE program Clinical Trial Eligibility Overview. Trial Name: NCT05609669 — N/A
Pregnancy Research Study Groups: CADENCE program pilot
Pregnancy Clinical Trial 2023: CADENCE program Highlights & Side Effects. Trial Name: NCT05609669 — N/A
CADENCE program 2023 Treatment Timeline for Medical Study. Trial Name: NCT05609669 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are participants currently being sought for this clinical experiment?

"Clinicaltrials.gov has confirmed that this study, which was initially published on October 1st 2023 and most recently revised on November 2nd 2022, is no longer recruiting participants. However, there are 420 other trials accepting new volunteers at the moment."

Answered by AI

What benchmarks is this clinical trial looking to achieve?

"The primary goal of this research, measured at the time of delivery hospitalization, is to reduce pharmacologically treated neonatal outcomes. Additionally, it seeks to evaluate prenatal care adequacy via a Kotelchuck index score as well as first trimester entry into such services and total length of stay for newborns during their admission period."

Answered by AI
~5 spots leftby Sep 2024